Biotechnology company Axsome Therapeutics (NASDAQ: AXSM) has performed well this year, with its stock price up 16% year-to-date, outperforming the S&P 500's 11% gain. Wall Street analysts are optimistic about its prospects, with an average price target of $285.42, implying an upside potential of approximately 37% from current levels. The company has recently made significant clinical and regulatory progress, including the approval of Auvelity for the treatment of depression, and its expanded indication in April this year for Alzheimer's disease (AD) agitation. In the second quarter, the company's revenue increased by 46% year-over-year to $218.4 million, with Auvelity contributing $180.3 million in net product sales, a 51% year-over-year increase. Furthermore, the company has several drugs in late-stage development, and its product portfolio's peak sales are expected to exceed $16 billion in the coming years.